JP2017508144A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017508144A5 JP2017508144A5 JP2016551166A JP2016551166A JP2017508144A5 JP 2017508144 A5 JP2017508144 A5 JP 2017508144A5 JP 2016551166 A JP2016551166 A JP 2016551166A JP 2016551166 A JP2016551166 A JP 2016551166A JP 2017508144 A5 JP2017508144 A5 JP 2017508144A5
- Authority
- JP
- Japan
- Prior art keywords
- sortilin
- kit according
- bipolar disorder
- subject
- subjects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100032889 Sortilin Human genes 0.000 claims 18
- 108010014657 sortilin Proteins 0.000 claims 18
- 208000020925 Bipolar disease Diseases 0.000 claims 13
- 208000020401 Depressive disease Diseases 0.000 claims 8
- 201000003104 endogenous depression Diseases 0.000 claims 8
- 208000024714 major depressive disease Diseases 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 5
- 239000000090 biomarker Substances 0.000 claims 4
- 238000005259 measurement Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 229940125681 anticonvulsant agent Drugs 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 229940005529 antipsychotics Drugs 0.000 claims 1
- 229960004372 aripiprazole Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 229960001848 lamotrigine Drugs 0.000 claims 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims 1
- 229940008015 lithium carbonate Drugs 0.000 claims 1
- 229910052808 lithium carbonate Inorganic materials 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 229960004431 quetiapine Drugs 0.000 claims 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 1
- 229960001534 risperidone Drugs 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229940102566 valproate Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201400075 | 2014-02-12 | ||
| DKPA201400075 | 2014-02-12 | ||
| PCT/EP2015/052506 WO2015121166A1 (en) | 2014-02-12 | 2015-02-06 | Use of sortilin as biomarker for affective/mood disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017508144A JP2017508144A (ja) | 2017-03-23 |
| JP2017508144A5 true JP2017508144A5 (OSRAM) | 2018-03-22 |
Family
ID=52462923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551166A Pending JP2017508144A (ja) | 2014-02-12 | 2015-02-06 | 感情／気分障害のバイオマーカーとしてのソルチリンの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160349276A1 (OSRAM) |
| EP (1) | EP3105594A1 (OSRAM) |
| JP (1) | JP2017508144A (OSRAM) |
| CN (1) | CN105980858A (OSRAM) |
| HK (1) | HK1232289A1 (OSRAM) |
| WO (1) | WO2015121166A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX393951B (es) | 2015-04-07 | 2025-03-24 | Alector Llc | Anticuerpos antisortilina y métodos para su uso. |
| US10849992B1 (en) | 2015-04-07 | 2020-12-01 | Alector Llc | Methods of screening for sortilin binding antagonists |
| FR3057267A1 (fr) * | 2016-10-11 | 2018-04-13 | Centre National De La Recherche Scientifique - Cnrs - | Procede de diagnostic/determination de l'efficacite de traitement de la depression |
| US11491120B2 (en) | 2017-11-09 | 2022-11-08 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| US11622948B2 (en) | 2017-11-09 | 2023-04-11 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| CA3060547A1 (en) | 2018-07-13 | 2020-01-13 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
| CN111351945B (zh) * | 2020-03-18 | 2021-04-23 | 东南大学 | 维生素d结合蛋白作为标志物在精神疾病抑郁症诊断中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105641694B (zh) * | 2008-12-19 | 2020-08-14 | H.隆德贝克有限公司 | 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节 |
| GB0903417D0 (en) * | 2009-02-27 | 2009-04-08 | Cambridge Entpr Ltd | Biomarkers |
| GB0922240D0 (en) * | 2009-12-21 | 2010-02-03 | Cambridge Entpr Ltd | Biomarkers |
| GB201021502D0 (en) * | 2010-12-20 | 2011-02-02 | Cambridge Entpr Ltd | Biomarkers |
-
2015
- 2015-02-06 CN CN201580008112.4A patent/CN105980858A/zh active Pending
- 2015-02-06 JP JP2016551166A patent/JP2017508144A/ja active Pending
- 2015-02-06 EP EP15703275.6A patent/EP3105594A1/en not_active Withdrawn
- 2015-02-06 WO PCT/EP2015/052506 patent/WO2015121166A1/en not_active Ceased
- 2015-02-06 US US15/117,967 patent/US20160349276A1/en not_active Abandoned
- 2015-02-06 HK HK17105802.8A patent/HK1232289A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017508144A5 (OSRAM) | ||
| Jha et al. | Frailty in advanced heart failure: a systematic review | |
| Sato et al. | Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease | |
| JP6364488B2 (ja) | 認知欠損を治療するための個別化医療的手法 | |
| HK1258292A1 (zh) | 使用il23途徑生物標誌物預測il23拮抗劑的臨床應答 | |
| Skevaki et al. | Immune biomarkers in the spectrum of childhood noncommunicable diseases | |
| WO2013040099A3 (en) | Sepsis prognosis biomarkers | |
| CN105389465A (zh) | 病历数据处理方法、装置以及系统 | |
| Addissouky | Detecting liver fibrosis by recent reliable biomarkers in viral hepatitis patients | |
| NZ594772A (en) | Diagnosis and prognosis of renal injury and renal failure using vitamin k dependent protein c | |
| Biedermann et al. | Agreement between Coaguchek XS and STA-R Evolution (Hepato Quick) INR results depends on the level of INR | |
| MX2018007589A (es) | Ccl20 como indicador de respuesta clinica a antagonistas de il23. | |
| RU2019103403A (ru) | Адреномедуллин для оценки застоя у индивидуума с острой сердечной недостаточностью | |
| BR112014018204A8 (pt) | Método de diagnóstico de distúrbio de células beta pancreáticas em um indivíduo | |
| Ligon et al. | Biomarkers in scleroderma: progressing from association to clinical utility | |
| Lee et al. | Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia | |
| JP2015528562A5 (OSRAM) | ||
| JP2011196840A (ja) | 急性大動脈解離の検査方法 | |
| Petramala et al. | Aldosterone-induced oxidative stress: a potential mechanism of aldosterone autonomy in primary aldosteronism | |
| Branford | Monitoring and defining early response: where to draw the line? | |
| JP2015503106A5 (OSRAM) | ||
| SG10201709117RA (en) | In Vitro Diagnostic Method For Alzheimer's Disease Based On The Albumin Redox Level In The Cerebrospinal Fluid | |
| PL422387A1 (pl) | Sposób oznaczania wrażliwości tkanek na insulinę, sposób identyfikacji insulinooporności i/lub określania predyspozycji do zaburzenia z nią związanego, zastosowanie wskaźnika insulinowrażliwości oraz zestawy diagnostyczne i ich zastosowania | |
| Saini et al. | The PROFILE study: A prospective study of fibrosis in lung endpoints to discover and qualify biomarkers for use in clinical trials | |
| Fuster et al. | Is erythrocyte sedimentation rate a useful inflammatory marker independently of the hematocrit? Comparison results with plasma viscosity |